Clinical validation of the iXip index in avoiding unnecessary prostate biopsy: Results from a prospective multicenter study involving 426 patients

Schröder, 2009, Defining the optimal prostate-specific antigen threshold for the diagnosis of prostate cancer, Curr. Opin. Urol., 19, 227, 10.1097/MOU.0b013e328329a2d0 Ukimura, 2013, Contemporary role of systematic prostate biopsies: indications, techniques, and implications for patient care, Eur. Urol., 63, 214, 10.1016/j.eururo.2012.09.033 Auprich, 2011, Contemporary role of prostate cancer antigen 3 in the management of prostate cancer, Eur. Urol., 60, 1045, 10.1016/j.eururo.2011.08.003 Filella, 2013, Evaluation of [-2]proPSA and Prostate Health Index (phi) for the detection of prostate cancer: a systematic review and meta-analysis, Clin. Chem. Lab. Med., 51, 729, 10.1515/cclm-2012-0410 Konety, 2015, The 4Kscore® test reduces prostate biopsy rates in, community and academic urology practices, Rev. Urol., 17, 231 Beneduce, 2007, Detection of prostate-specific antigen coupled to immunoglobulin M in prostate cancer patients, Cancer Detect. Prev., 31, 402, 10.1016/j.cdp.2007.10.005 Beneduce, 2005, Squamous cell carcinoma antigen-immunoglobulin M complexes as novel biomarkers for hepatocellular carcinoma, Cancer, 103, 2558, 10.1002/cncr.21106 Castaldi, 2005, Detection of circulating CEA-IgM complexes in early stage colorectal cancer, Int. J. Biol. Markers, 20, 204, 10.1177/172460080502000402 Gallotta, 2013, A novel algorithm for the prediction of prostate cancer in clinically suspected patients, Cancer Biomark., 13, 227, 10.3233/CBM-130357 Bossuyt, 2003, The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration, Clin. Chem., 49, 7, 10.1373/49.1.7 Epstein, 2005, The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma, Am. J. Surg. Pathol., 29, 1228, 10.1097/01.pas.0000173646.99337.b1 Guazzoni, 2011, Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting, Eur. Urol., 60, 214, 10.1016/j.eururo.2011.03.052 Lazzeri, 2013, Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10 ng/ml: a multicentric European study, Eur. Urol., 63, 986, 10.1016/j.eururo.2013.01.011 Hanley, 1982, The meaning and use of the area under a receiver operating characteristic (ROC) curve, Radiology, 143, 29, 10.1148/radiology.143.1.7063747 Marks, 2007, PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy, Urology, 69, 532, 10.1016/j.urology.2006.12.014 Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group, 2014, Recommendations from the EGAPP Working Group: does PCA3 testing for the diagnosis and management of prostate cancer improve patient health outcomes?, Genet. Med., 16, 338, 10.1038/gim.2013.141 Carignan, 2012, Increasing risk of infectious complications after transrectal ultrasound-guided prostate biopsies: time to reassess antimicrobial prophylaxis?, Eur. Urol., 62, 453, 10.1016/j.eururo.2012.04.044 Nam, 2013, Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy, J. Urol., 189, S17 Loeb, 2013, Systematic review of complications of prostate biopsy, Eur. Urol., 64, 876, 10.1016/j.eururo.2013.05.049